"Antigen-specific active immunotherapy for ovarian cancer is not supported by sufficient good quality evidence. Consideration could be given to using it only within the context of a research or audit project.
Reducing or stopping antigen-specific active immunotherapy for ovarian cancer is likely to improve the quality of patient care by reducing exposure to unproven therapies and result in productivity savings."
Antigen-specific active immunotherapy for ovarian cancer (Quality and productivity collection examples)
The UK Cochrane Centre and NICE
November 2014
Read more here.
No comments:
Post a Comment